EQ-5D-5L Update Reshapes Cancer Economics

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: NICE's major EQ-5D-5L consultation reshaping cost-effectiveness, CHMP approvals including rare disease treatments, and JCA device expansion. Let's get into it.

SaraThe NICE EQ-5D-5L consultation is fascinating for what it reveals about embedded bias in our current framework. Their impact assessment of 37 published appraisals shows cancer medicines becoming more cost-effective with the new value set, while quality-of-life-only improving therapies see a median 59% ICER increase.

MarcusThat's a predictable outcome when you're replacing 1990s data with contemporary health state valuations. But I'm more interested in the methodological implications. We're finally moving away from a value set that predates most modern therapeutic classes.

SaraPredictable, yes, but problematic from a portfolio strategy perspective. This isn't just a technical update - it's systematically advantaging oncology assets while penalizing quality-of-life interventions. Mental health, chronic pain management, rare disease symptomatic treatments - they're all getting squeezed.

MarcusBut that assumes the current valuations are correct. If contemporary patients genuinely value health states differently than they did 30 years ago, then these shifts reflect real preference changes, not arbitrary bias.

SaraReal preference changes influenced by what, exactly? Societal attitudes? Healthcare expectations? This consultation runs until May 27th, but I doubt NICE will address whether we're capturing genuine value evolution or just recalibrating to current therapeutic landscapes.

MarcusFair point, but we can't preserve outdated methodology just to protect certain therapeutic areas. The evidence base needs updating.

SaraMoving to CHMP approvals - they recommended eight medicines at their May meeting, including Jascayd for idiopathic pulmonary fibrosis. Rare diseases with progressive deterioration like IPF represent exactly the kind of unmet need where traditional QALY calculations break down.

MarcusIPF is a perfect example of where clinical urgency should drive approval decisions. Progressive lung scarring with limited treatment options - the evidence bar has to be different.

SaraBut that's where I disagree. Clinical urgency doesn't automatically justify relaxed evidence standards. We've seen too many rare disease approvals based on surrogate endpoints that don't translate to meaningful patient outcomes.

MarcusNerandomilast went through standard CHMP review. They're not rubber-stamping applications.

SaraStandard review, yes, but with implicit bias toward approval in rare diseases with high unmet need. The question is whether we're being rigorous enough about long-term benefit-risk profiles.

MarcusYou're asking patients with progressive fatal conditions to wait for perfect evidence that may never come. Sometimes regulatory pragmatism is appropriate.

SaraThe JCA expansion into medical devices starting June 2026 is where things get really complex. Class IIb and III devices joining oncology and ATMP assessments means we're applying pharmaceutical evidence frameworks to completely different innovation paradigms.

MarcusThe methodology guidance addresses evidence gaps, but you're right about paradigm mismatches. Device iterative improvement cycles don't align well with fixed assessment timepoints.

SaraExactly. And with scientific advice slots capped at 17 total - 8-12 medicines, 2-5 medical devices - we're creating artificial scarcity in pre-submission guidance right when manufacturers need it most.

MarcusThat capacity constraint is telling. Either HTACG is under-resourced for the expanded scope, or they're deliberately limiting engagement to manage workload.

SaraI suspect both. But the real issue is whether device manufacturers will adapt their development strategies to JCA requirements or simply avoid European markets where possible.

MarcusGiven the market size, avoidance isn't realistic. They'll adapt, but probably with increased development timelines and costs that ultimately affect innovation pace.

SaraNICE's new prioritisation framework with monthly board meetings and unified guidance portfolio targeting NHS operational priorities is smart positioning. Focusing on digital mental health therapies for workforce constraints directly addresses system pressures.

MarcusIt's pragmatic, but I'm concerned about mission creep. When HTA bodies start prioritising based on operational convenience rather than clinical value, we're moving away from evidence-based assessment.

SaraBut clinical value in isolation from system capacity is meaningless. If the NHS can't implement guidance because of workforce constraints, what's the point of producing it?

MarcusThat's a resource allocation problem, not an HTA methodology problem. We shouldn't corrupt scientific assessment with operational expediency.

SaraThe MHRA-NICE aligned pathway progressing toward June guidance will test exactly that tension. Faster approvals mean compressed evidence review cycles.

MarcusTrue, but alignment could also mean more coherent regulatory-HTA signal. We'll see whether speed comes at the expense of rigor.

SaraThese developments collectively represent tighter evidence requirements, expanded EU scrutiny, and evolving value frameworks. Market access strategies need fundamental recalibration.

MarcusAgreed. The EQ-5D-5L update alone will reshape cost-effectiveness models across multiple therapeutic areas. Combined with JCA device expansion and new prioritisation approaches, we're looking at a significantly different access landscape.

SaraBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.